Chicago Equity Partners LLC bought a new position in Bioverativ Inc (NASDAQ:BIVV) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 9,320 shares of the biotechnology company’s stock, valued at approximately $532,000.

Other institutional investors and hedge funds also recently modified their holdings of the company. Whittier Trust Co. of Nevada Inc. acquired a new position in shares of Bioverativ in the 3rd quarter worth approximately $293,000. Rockefeller Financial Services Inc. acquired a new stake in Bioverativ during the 3rd quarter valued at $1,480,000. Quotient Investors LLC acquired a new stake in Bioverativ during the 3rd quarter valued at $420,000. Oakbrook Investments LLC acquired a new stake in Bioverativ during the 3rd quarter valued at $327,000. Finally, Raymond James Trust N.A. acquired a new stake in Bioverativ during the 3rd quarter valued at $297,000. 95.16% of the stock is owned by institutional investors and hedge funds.

Shares of Bioverativ Inc (BIVV) opened at $56.11 on Friday. Bioverativ Inc has a 52 week low of $40.00 and a 52 week high of $64.41.

Bioverativ (NASDAQ:BIVV) last released its earnings results on Thursday, October 26th. The biotechnology company reported $0.80 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.55 by $0.25. The company had revenue of $291.60 million during the quarter, compared to analysts’ expectations of $285.45 million. Bioverativ had a return on equity of 69.03% and a net margin of 40.44%. The firm’s revenue for the quarter was up 27.2% compared to the same quarter last year. analysts expect that Bioverativ Inc will post 2.45 EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Chicago Equity Partners LLC Buys Shares of 9,320 Bioverativ Inc (BIVV)” was originally posted by Daily Political and is the sole property of of Daily Political. If you are accessing this story on another publication, it was illegally copied and republished in violation of U.S. & international trademark and copyright legislation. The correct version of this story can be viewed at https://www.dailypolitical.com/2017/11/18/chicago-equity-partners-llc-buys-shares-of-9320-bioverativ-inc-bivv.html.

A number of equities research analysts recently weighed in on BIVV shares. Zacks Investment Research cut Bioverativ from a “strong-buy” rating to a “hold” rating in a report on Wednesday, November 1st. Jefferies Group LLC reaffirmed a “buy” rating and set a $70.00 price target (up from $67.00) on shares of Bioverativ in a report on Wednesday, August 9th. Argus raised Bioverativ from a “hold” rating to a “buy” rating and set a $64.00 price target for the company in a report on Wednesday, September 20th. Cowen and Company reaffirmed a “buy” rating and set a $80.00 price target on shares of Bioverativ in a report on Friday, August 4th. Finally, Evercore ISI started coverage on Bioverativ in a report on Wednesday, August 16th. They set an “in-line” rating and a $58.00 price target for the company. One analyst has rated the stock with a sell rating, nine have given a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. Bioverativ currently has a consensus rating of “Hold” and an average price target of $61.73.

Bioverativ Profile

Bioverativ Inc (Bioverativ) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein], and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively.

Institutional Ownership by Quarter for Bioverativ (NASDAQ:BIVV)

Receive News & Ratings for Bioverativ Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioverativ Inc and related companies with MarketBeat.com's FREE daily email newsletter.